Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 15/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23209150 | 0.87 | TRPA1 (0.53) | TRPA1 | |
| SCHEMBL23209149 | 0.87 | TRPA1 (0.53) | TRPA1 | |
| SCHEMBL24689347 | 0.86 | TRPA1 (0.42) | TRPA1 | |
| SCHEMBL23237684 | 0.86 | TRPA1 (0.46) | TRPA1 | |
| SCHEMBL23237543 | 0.86 | TRPA1 (0.45) | TRPA1 | |
| SCHEMBL23237637 | 0.85 | TRPA1 (0.47) | TRPA1 | |
| SCHEMBL24689137 | 0.82 | MAPT (0.45) | TRPA1L3MBTL1AOC3 | |
| SCHEMBL24689130 | 0.78 | TRPA1 (0.37) | TRPA1 | |
| SCHEMBL23236876 | 0.77 | TRPA1 (0.51) | TRPA1 | |
| SCHEMBL4883555 | 0.77 | TSHR (0.48) | KMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340590-A1 | 3H,4H-THIENO[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-10-27 | — | — | US | disclosed |
| US-11136336-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20210107918-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107918-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885KMT2A 4482/4885L3MBTL1 4178/4885 |
| US-20220340590-A1 | 3H,4H-THIENO[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885KMT2A 4448/4885L3MBTL1 3982/4885 |
| US-11136336-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885KMT2A 4501/4885L3MBTL1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.